Auxilium Pharmaceuticals Inc

Auxilium Pharmaceuticals — Investor Day (October 2007)

188 slides from Auxilium Pharmaceuticals's investor day presentation, Oct 17, 2007

  1. Slide 1: Welcome to Auxilium's First Analyst Day – Focusing on Xiaflex

    Welcome to Auxilium’s First Analyst Day – Focusing on Xiaflex! October 17, 2007 Exhibit 99.1

  2. Slide 2: Armando Anido, Chief Executive Officer and President

    Armando Anido Chief Executive Officer and President

  3. Slide 3: Safe Harbor Statement

    Safe Harbor Statement We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding future Testim market share and sales growth a

  4. Slide 4: Today's Agenda

    Today’s Agenda Who is AUXL Overview of XIAFLEX™ Dupuytren’s Contracture ~ Disease overview & treatment options ~ Clinical Development Plan ~ Market Overview Peyronie’s Disease ~ Disease overview & treatment options ~ Clinical Development Plan ~ Market Overview Questions and Answers

  5. Slide 5: Ground Rules For The Day

    Ground Rules For The Day • Please hold all questions until after we finish the formal presentations. • We will limit each person to 1 question, then allow you to get back in the queue • We may limit responses from our guest speakers to preserve competitive data or intellectual property rights •Speak

  6. Slide 6: Medical Experts Participating Today

    Medical Experts Participating Today • Larry Hurst, M.D., Professor and Chair, Chief of Hand Surgery, Department of Orthopaedics of the Health Science Center, State University of New York at Stony Brook • Gerald H. Jordan, M.D., F.A.C.S., F.A.A.P., Professor, Department of Urology, Eastern Virginia M

  7. Slide 7: Participating from Auxilium

    Participating from Auxilium Jim Fickenscher, Chief Financial Officer Roger Graham, Executive Vice President, Sales & Marketing Dr. Jyrki Mattila, Executive Vice President, Business Development, R&D and Technical Operations

  8. Slide 8: Fastest Growing TRT Product, Late Stage Company

    Fastest Growing TRT product in the U.S. Late Stage Company Transforming Product Poised for Growth + =

  9. Slide 9: Auxilium Pharmaceuticals, Inc.

    Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) • Specialty biopharmaceutical company focused on Urologists, Endocrinologists, Orthopedists and certain PCPs • Founded in 1999 • Headquarters in Malvern, Pa . ~ Manufacturing in Horsham, Pa. ~ Approximately 2

  10. Slide 10: Broad Pipeline Maturing in Coming Years

    Market Phase III Phase II Phase I Hypogonadism Dupuytren’s Contracture Peyronie’s Disease Frozen Shoulder Syndrome Overactive Bladder Broad Pipeline Maturing in Coming Years Broad Pipeline Maturing in Coming Years Note: Worldwide rights for all products available, except Testim where ex -U.S. rights

  11. Slide 11: XIAFLEX – Company Transforming Opportunity

    XIAFLEX – XIAFLEX – Company Transforming Company Transforming Opportunity Opportunity • Potential to replace surgery • Great fit for Specialty Biopharmaceutical Company • Worldwide rights offer options to build company or generate cash • We believe there are approximately 450,000 potential patients

  12. Slide 12: Overview of XIAFLEX

    Overview of XIAFLEX™ (Clostridial Collagenase for Injection)

  13. Slide 13: XIAFLEX

    XIAFLEX™ • Purified Clostridial Collagenase for injection • Specific combination of several subtypes of Collagenase • Produced by bacterial fermentation & purified at our Horsham facility • Filled and lyophilized by a third party manufacturing partner • Requires reconstitution with sterile diluent b

  14. Slide 14: Mechanism of Action

    Mechanism of Action • Collagen is a molecule made up of three peptide chains arranged as an alpha-triple helix ~ Renders collagen impervious to all proteolytic enzymes except collagenase Endogenous collagenases ~ May be deficient in Dupuytren’s & Peyronie’s patients ~ Degrade collagen at one site &

  15. Slide 15: XIAFLEX

    XIAFLEX™ • Over 1,300 patients have been exposed to XIAFLEX™ in a range of indications • 237 Dupuytren’s patients have been treated • 280 Peyronie’s patients have been treated

  16. Slide 16: Development History

    Development History • First formulated in the 1980’s • Initial trials in Peyronie’s Disease – 1982 • Initial trials in Dupuytren’s Contracture – 1996 • Orphan Drug Designations Granted ~ Dupuytren’s Contracture – 1996 ~ Peyronie’s Disease – 1997 Auxilium Obtains License to AA4500 - 2004 • Initial Du

  17. Slide 17: Development History

    Development History • New manufacturing process developed – 2004 to 2006 • Option exercised for Frozen Shoulder – December, 2005 • Horsham manufacturing facility acquired – August, 2006 • Results announced from ~ Initial Phase 3 study in Dupuytren’s contracture – June, 2006 ~ Phase 2 studies in Peyr

  18. Slide 18: Lawrence C. Hurst, MD

    Lawrence C. Hurst, MD Current Professional Appointments: ~ Professor & Chairman; Chief, Division of Hand Surgery, Department of Orthopaedics, SUNY @ Stony Brook School Of Medicine ~ Program Director, Hand Fellowship Training ~ Adjunct Staff/Hand Surgery: St. Charles Hospital, Port Jefferson, NY Educ

  19. Slide 19: Dupuytren's Disease

    Dupuytren’s Disease. IK

  20. Slide 20: History of Dupuytren's Disease

    History of Dupuytren’s Disease (DD) • Orkney and Iceland in th & th writings mention DD • Felix Plater of Basel describes DD in 1614 but thought pathology secondary to tendon problem • John Hunter accurately describes DD in 1777 – the year of Dupuytren’s birth • Ashley Copper writes about DD in “A t

  21. Slide 21: History

    History The eponym for Dupuytren Disease was coined because M. Dupuytren performed a fasciotomy using an open transverse incision in 1831

  22. Slide 22: History of DD

    History of DD Despite Dupuytren’s famous open surgical treatment, Ashley Cooper’s closed fasciotomy was the treatment of choice but neither procedure was used frequently until anesthesia was added in 1842 and Lister’s antiseptic techniques were added in 1865.

  23. Slide 23: Dupuytren's Disease

    Dupuytren’s Disease _ Lawrence C..Hurst;MD University Hand Cent

  24. Slide 24: Histology, Cell Biology & Biochemistry

    HISTOLOGY, CELL BIOLOGY & BIOCHEMISTRY The Myofibroblast and Attached collagen Electron Microscopic view of a Myofibroblast

  25. Slide 25: Histology, Cell Biology & Biochemistry

    HISTOLOGY, CELL BIOLOGY & BIOCHEMISTRY Increased collagen type III & GAG’s Collagen helix pattern with increased cross- links Fibrotactin - an extracellular matrix- cytoskeletal connector

  26. Slide 26: Dupuytren's Disease

    Dupuytren’s Disease _ Lawrence C..Hurst;MD University Hand Cent

  27. Slide 27: Dupuytren's Disease – Normal

    Dupuytren’s Disease| NORMAL

  28. Slide 28: Dupuytren's Disease – Abnormal

    Dupuytren’s Disease| ABNORMAL

  29. Slide 29: Pathoanatomy: Common Pathologic Cords

    PATHOANATOMY Common Pathologic Cords Central Cord Lateral Cord Natatory Cord Pretendinous Cord Spiral Cord Nodule

  30. Slide 30: Pathoanatomy

    PATHOANATOMY Digital Nerve and Vessel Spiral Cord Note: Cord Actually Straight and the Neurovascular bundle spirals!

  31. Slide 31: Incidence, Genetics, Associated Diseases, Ectopic Locations

    Incidence • Genetics Associated Diseases Ectopic Locations

  32. Slide 32: Incidence

    INCIDENCE Mikkelsen in Norway found 9% incidence in males & 3% incidence in females Incidence: near 5% before age 20 above 20% at age 70 Brenner (2001) found 1.9 Million Germans affected

  33. Slide 33: Dupuytren's Disease Incidence by Age

    Dupuytren’s Disease ™ Incidence (%) Age (yrs.)

  34. Slide 34: Genetics: Autosomal Dominant

    GENETICS: Autosomal dominant Mendelian Inheritance pattern with variable penetrance:

  35. Slide 35: Ectopic Fibromatoses

    ECTOPIC FIBROMATOSES: - Foot – Plantar fibromatosis (Ledderhose) - Penile Fibromatosis (Peyronie) - Knuckle Pads

  36. Slide 36: Ectopic Fibromatoses

    ECTOPIC FIBROMATOSES: - Foot – Plantar fibromatosis (Ledderhose)

  37. Slide 37: Treatment Options – Current Option: Surgery

    Treatment Options Current Option - Surgery

  38. Slide 38: Surgical Indications

    Surgical Indications • 30 Degree MP Contracture • Any PIP Contracture • Nodule Over Trigger Finger Requiring Surgery • Anesthesia – Match type with Patient & Contracture-Local, Axillary Block or General

  39. Slide 39: Surgical Indications

    Surgical Indications • Positive Table Top Test The Dupuytren’s cord causes flexion contractures so that the palm and the fingers CAN NOT be placed on the same flat surface simultaneously !!

  40. Slide 40: Surgical indications suggest operating on mild contractures

    • These surgical indications suggest that surgeons recommend operative treatment for rather mild contractures. Why are these the standard textbook indications?

  41. Slide 41: Progressive, severe contractures are difficult to correct

    • Progressive - sometimes even aggressive. • Severe contractures are very difficult to correct surgically • Severe contractures can interfere significantly with activities of daily living (ADL)

  42. Slide 42: Severe Contracture Can Cause Hygiene Problem

    Severe Contracture Can Cause Hygiene Problem Pre-op photo shows Dupuytren’s cord eroding through the skin pit base at first flexion crease of the finger

  43. Slide 43: Imagine this hand getting into this pocket

    Imagine this hand easily getting into this pocket??

  44. Slide 44: Imagine this hand holding this mug of beer

    Imagine this hand holding this mug of beer?

  45. Slide 45: Imagine this hand trying to wash your face

    Imagine this hand trying to wash your face?

  46. Slide 46: Imagine this hand shaking your hand

    Imagine this hand shaking your hand?

  47. Slide 47: Many incisions have been tried over last century

    Many incisions have been tried over last century No incision has made surgery simple; always successful or guaranteed a long term correction!

  48. Slide 48: Common Incisions for Operative Management

    COMMON USED INCISONS FOR OPERATIVE MANAGEMENT ARE: Brunner(zig-zag plasty), Standard Z-plasty, Or McCash (Transverse)

  49. Slide 49: Operative Management in DD

    Operative Management in DD Distally Based Flap

  50. Slide 50: Operative anatomy

    |skoog’s ligament us band cular Bun

  51. Slide 51: Operative Management in DD: Spiral Cords

    Operative Management in DD Spiral Cords Digital nerve superficial to the spiral cord Spiral cord moves N-V Bundle Proximally, Centrally and Superficially

  52. Slide 52: Dupuytren's Disease

    |/Dupuytren’s Disease

  53. Slide 53: Pre-tendonous Cord

    Pre-tendonous Cord in: Cord out: Excised Dupuytren’s Cord

  54. Slide 54: With tourniquet down

    With tourniquet down check: Flap vascularity:

  55. Slide 55: Surgical Treatment can be very extensive

    Surgical Treatment can be very extensive !

  56. Slide 56: Open Palm (McCash) Technique

    Operative Management in DD : OPEN Palm ( McCash ) Technique At Surgery 2-3 Months Post-op

  57. Slide 57: Operative Management of DD in the Radial Side of the Hand

    Operative Management of DD in the Radial Side of the Hand: Contracting Web Superficial and Deep Commissurial Cords

  58. Slide 58: Skin Grafts

    Skin Grafts Cord tissue New Skin graft Healed graft from previous surgery Skin Grafts

  59. Slide 59: Lawrence C. Hurst, MD

    Lawrence. C..| H urst;,MD

  60. Slide 60: Prognosis – McFarlane

    PROGNOSIS – Mc Farlane 1202 Surgical patients 6-18 months Follow-up: -19% Perfect - 56% Improved - 25% same or worse

  61. Slide 61: Closed fasciotomy can be dangerous

    Another Surgical Option is the Closed fasciotomy which CAN BE DANGEROUS! Why? - Because This NERVE Might Be Right Here!

  62. Slide 62: Needle fasciotomy can be dangerous to digital nerves

    Another Surgical Option is the Needle fasciotomy. This too can be dangerous to digital nerves.

  63. Slide 63: Operative Management in DD: Needle fasciotomy

    Operative Management in DD: Needle fasciotomy

  64. Slide 64: Needle fasciotomy Nerve, follow-up

    Operative Management in DD: Needle fasciotomy Nerve, f/u

  65. Slide 65: Non-Operative Management: XIAFLEX

    Non-Operative Management: XIAFLEX • Indications = Surgical Indications !

  66. Slide 66: Non-Operative Management: XIAFLEX

    Non-Operative Management: XIAFLEX* *Currently not FDA approved .25 CC’s for MP and .20 CC’s for PIP Each with 0.58 mg of Xiaflex which equals 10,000 units

  67. Slide 67: XIAFLEX Target areas for injection

    Non-Operative Management: XIAFLEX* Distal End Of Cord Proximal End Of Cord Area of Maximal “Bowstringing” (Separation of Cord and Flexor Tendons) Target areas for Xiaflex Injection *Currently not FDA approved

  68. Slide 68: Non-Operative Management: XIAFLEX

    Non-Operative Management: XIAFLEX* *Currently not FDA approved 1/3 of dose in three separate places In the cord (not through the cord)

  69. Slide 69: Non-Operative Management

    Non-Operative Management The needle should be placed in, not through the gritty gristly consistency of the cord (can be palpated with the end of the needle)

  70. Slide 70: Non-Operative Management of Y Shaped Cord

    Non-Operative Management of “Y” Shaped Cord *Currently not FDA approved 1/3 of dose in three separate places In the cord (not through the cord) • Created by a combination of a central and natatory cord • The “point” of the Y should be injected

  71. Slide 71: XIAFLEX Clinical Study Results

    XIAFLEX Clinical Study Results

  72. Slide 72: Summary of Clinical Studies

    Summary of Clinical Studies Total § Open label study of the relative safety and efficacy of collagenase therapy in the treatment of residual type Dupuytren’s disease. DUPY- (continuat ion from - 303) (12 of 35 subjects had placebo only) Double-blind randomized, placebo controlled study of the relati

  73. Slide 73: Overview Of Clinical Data

    Overview Of Clinical Data • 215 patients with Dupuytren’s contracture treated with Xiaflex – 0.58mg per injection appears to be the most effective dosage – One Phase 3 study with 35 patients completed

  74. Slide 74: Overview (cont.)

    Overview (cont.) • Two double-blind, placebo controlled trials – One Phase 2: 80 subjects – One Phase 3: 35 subjects • Clinical Success: return to within –5 of normal O O

  75. Slide 75: Efficacy Profile - DUPY Double Blind Exploratory

    Efficacy Profile - DUPY 101 Double Blind Exploratory • One injection • 49 subjects • AA4500 Success (Primary Joint) – MP 14/18 = 78% – PIP 5/7 = 71% JHS 27A, 5, p.788-798 (2002)

  76. Slide 76: Efficacy Profile - DUPY Double Blind Phase

    Efficacy Profile - DUPY 202 Double Blind Phase 2 • One injection • 80 subjects • AA4500 Success (Primary Joint) – MP 13/16 = 81% – PIP 5/7 = 71% JHS 27A, 5, p.788-798 (2002)

  77. Slide 77: Efficacy Profile - DUPY Double Blind Phase

    Efficacy Profile - DUPY 303 Double Blind Phase 3 XIAFLEX Placebo P-value Primary End Point 21/23 (91%)* < .001 - MP Joint 12/14 (86%) < .001 - PIP Joint 9/9 (100%) < .001 Secondary Joint 5/6 (83%) .035 Median Time to Success 8 Days N/A Mean # Injections For Success 1.4 N/A * Success rates were 70% a

  78. Slide 78: Efficacy Profile – Summary from DB studies

    Efficacy Profile – Summary from DB studies • MP joints: 81% (one injection) to 86% (multiple injections) • PIP joints: 71% (one injection) to 100% (multiple injections)

  79. Slide 79: Safety Profile

    Safety Profile (202 & 303) • Generally well tolerated • Treatment-related AEs confined to the local / administration site – Related to the injection or manipulation procedure of rupturing the cord • Mild or moderate, non-serious, transient, and resolved within 2 - 4 weeks without sequelae.

  80. Slide 80: Summary

    Summary •Excellent efficacy profile, ranging from 71% - 100% after up to three injections •Most achieved clinical success within one month •General well tolerated after multiple injections •AEs confined locally and were mild, moderate, and resolved with 2- 4 weeks •In 202, no indication of antibody

  81. Slide 81: Non-Operative Management: XIAFLEX

    Non-Operative Management: XIAFLEX* year old male complaining of inability to straighten his right little finger for the past 3 years. It “gets in my way!” Exam shows an MP contracture. post treatment *Currently not FDA approved

  82. Slide 82: Non-Operative Management: XIAFLEX

    Non-Operative Management: XIAFLEX* y.o. male with severe recurrent DD Of the long finer. post treatment *Currently not FDA approved

  83. Slide 83: Non-Operative Management: XIAFLEX

    Non-Operative Management: XIAFLEX* y.o. male complaining of a contracture of his left little finger present for five years. He can’t put his hand in his pocket and puts his finger in his eye while washing his face. Exam shows a PIP contracture post treatment *Currently not FDA approved

  84. Slide 84: Dupuytren's Disease

    Dupuytren’s Disease}

  85. Slide 85: Dupuytren's Disease

    Dupuytren’s Disease q Lawrence. C..Hurst,;MD University Hand ¢ Department Of Or

  86. Slide 86: Clinical Program for Dupuytren's Contracture

    Clinical Program for Dupuytren’s Contracture Jyrki Mattila Executive Vice President R&D

  87. Slide 87: Suspended Phase Studies

    Suspended Phase 3 Studies • First clinical trials utilizing XIAFLEX ™ manufactured under process developed by Auxilium • Six sites in Australia and United States participated • Thirty patients were treated ~ 22 received XIAFLEX ™ ~ 8 received placebo injections • of patients injected with XIAFLEX ™

  88. Slide 88: XIAFLEX Clinical Phase 3 Program

    Xiaflex ™ Clinical Phase 3 Program CORD I Phase 3 double blind study with open label extension in the United States CORD II Phase 3 double blind study with open label extension in Australia JOINT I Open label phase 3 study in the United States JOINT II Open label phase 3 study in Australia and Europ

  89. Slide 89: CORD I

    CORD I C ollagenase O ption for R eduction of D upuytren ’ s ------------------------- A Phase 3, Double-Blind, Randomized, Placebo - Controlled Study of Xiaflex ™ in the Treatment of Dupuytren’s Contracture

  90. Slide 90: Objectives – CORD I

    Objectives – CORD I Primary efficacy objective • Reducing the degree of contracture of the primary MP or PIP joints Secondary efficacy objective • Reducing the degree of contracture in multiple MP and PIP joints Safety Objective • Provide data on the tolerability of Xiaflex ™ up to months post first

  91. Slide 91: Study Design – CORD I

    Study Design – CORD I Total of 216 subjects will be enrolled in approximately 15 study sites in the United States • Subjects stratified by ~ the primary joint type (144 MP joints and 72 PIP joints) ~ severity of primary joint contracture (< > 50 ° /40 ° for MP/PIP joints, respectively) • Subjects ra

  92. Slide 92: Inclusion Criteria – CORD I

    Inclusion Criteria - CORD I Dupuytren’s Contracture of at least one finger, • At least 20 ° but no greater than 100 ° for MP joint • At least but no greater than 80 ° for PIP joint • Caused by a palpable cord that has never been treated with Xiaflex ™ . Subject has a positive “table top test”

  93. Slide 93: Treatment and Follow-up – CORD I

    Treatment and Follow-up – CORD I Double blind placebo controlled phase (3 month): • Maximum of 3 injections of study drug (Day 0, 30, and 60). • Follow-up visits will be 1, 7 and 30 days after each injection. Open label extension (9 months): Nine month follow-up after completion of the double blind

  94. Slide 94: Efficacy Definitions – CORD I

    Efficacy Definitions – CORD I PRIMARY EFFICACY ENDPOINT: • The proportion of subjects who achieve clinical success of the primary joint after up to three injections Clinical success : Reduction in contracture to < 5 ° of normal 30 days after last injection.

  95. Slide 95: Secondary efficacy endpoints – CORD I

    Secondary efficacy endpoints – CORD I Recorded for the primary joint • Clinical success after the first injection • Clinical improvement • Percent reduction from baseline in contracture • Percent change from baseline in range of motion • Time to reach clinical success Clinical improvement : A > 50%

  96. Slide 96: Expected Timeline – CORD I

    Expected Timeline – CORD I • Enrollment completed by end of 2007 • Top line results of the double blind portion available 2Q 2008 • 12 month follow-up completed by end of 2008 • Study ready for BLA submission early 2009

  97. Slide 97: CORD II

    CORD II 60 patients, following protocol similar to CORD I • 3 month double blind • 9 month open label Five study sites in Australia Top line data from the double blind portion expected to be available 2Q 2008

  98. Slide 98: JOINT I & II

    JOINT I & II J oint O pen - Label I njection N on - Surgical T reatment ------------------------- Phase 3, Open-Label Studies of the Safety and Efficacy of Xiaflex ™ in the Treatment of Dupuytren’s Contracture

  99. Slide 99: Design – JOINT I & II

    Design - JOINT I & II Objective : To evaluate the safety and efficacy of up to 5 injections of Xiaflex ™ in multiple joints of subjects with Dupuytren’s contracture • No placebo control, all subjects receive Xiaflex ™ • JOINT I includes approximately 10 sites in the United States and enrolls 100 sub

  100. Slide 100: Design – JOINT I & II

    Design - JOINT I & II • Inclusion and exclusion criteria same as in CORD I • Efficacy definitions same as in CORD I • Following safety endpoints will be monitored: ~ Adverse events ~ Clinical laboratory tests and vital signs ~ Grip strength of the treated hand ~ Immunogenicity

  101. Slide 101: Clinical Phase 3 Program Summary

    Clinical Phase 3 Program Summary : • All studies up and running at this point •Enrollment to CORD I and CORD II expected to complete by end of 2007 •Approximately 725 subjects are planned to be enrolled in total •Phase 3 program to complete to allow BLA submission early 2009

  102. Slide 102: Market Overview for XIAFLEX: Dupuytren's Disease

    Market Overview for XIAFLEX: Dupuytren ’ s Disease Roger D. Graham, Jr. Executive Vice President Sales & Marketing

  103. Slide 103: Market Research Methodology

    Market Research Methodology • Approximately 600 Orthopedic and Hand Surgeons ~ 415 U.S. Physicians ~ 193 E.U. Physicians Qualitative and Quantitative Research ~ on in depth interviews with KOLs (High Treaters) ~ Web based Surveys ~ Second quantitative study designed to provide 95% confidence level a

  104. Slide 104: Surgeon's Motivation To Use XIAFLEX

    Surgeon’s Motivation To Use XIAFLEX • Dissatisfied With Surgery ~ Flexion contractures often not fully corrected (especially PIP joints) ~ High rate of complications ~ Difficult to meet patients’ expectations Believe XIAFLEX Fills An Unmet Need ~ Earlier use than surgery ~ Appropriate for poor surgi

  105. Slide 105: Reimbursement and Surgical Costs

    Reimbursement and Surgical Costs • Reimbursement ~ All payers anticipate coverage for XIAFLEX, including EU ~ New CPT codes may be needed for injection & manipulation ~ Miscellaneous J-code at launch Surgical Costs - Ambulatory (99%) ~ $ 4,800* • In-patient Surgery ~ $12,000 ** * Pharmetrics ** Veri

  106. Slide 106: XIAFLEX Potential: Dupuytren's Contracture

    XIAFLEX Potential: Dupuytren’s Contracture Patients Seeking Treatment ~1.03M No Prior Surgery ~540,000 Had Surgery Previously ~490,000 Watchful Waiting ~270,000 Medical/ Surgical Treatment ~270,000 Medical/ Surgical Treatment ~125,000 Watchful Wait/ In Follow Up ~365,000 XIAFLEX Potential Candidates

  107. Slide 107: Xiaflex Commercial Opportunity

    Xiaflex Commercial Opportunity We believe: There is a pent-up demand for non-surgical therapy Surgeons and patients prefer non-invasive treatment Each patient on average has 2.2 joints which will require treatment; 49% have contractures in both hands Early data indicates on average 1.4 vials of XIAF

  108. Slide 108: Gerald H. Jordan, MD, FACS, FAAP

    Gerald H. Jordan, MD, FACS, FAAP Current Professional Appointments: ~ Professor Urology Department, Eastern Virginia Medical School ~ Director, The Devine Center For Genitourinary Reconstruction, Sentara Norfolk General Hospital Education: ~ MD Degree: University of Texas Health Sciences Center Medi

  109. Slide 109: Peyronie's Disease

    Gerald H. Jordan, MD Department of Urology Eastern Virginia Medical School Norfolk, VA Peyronie’s Disease Gerald H. Jordan, MD Department of Urology Eastern Virginia Medical School Norfolk, VA

  110. Slide 110: Peyronie's disease is a scarring phenomenon of the tunica albuginea

    Peyronie’s disease is a scarring phenomenon affecting the tunica albuginea of the penis ¹ Scar tissue forms “plaques” that can result in pain with erection, penile curvature/deviation, penile shortening, indentations, and/or erectile dysfunction Histological staining shows fibrin accumulation and ex

  111. Slide 111: Peyronie's Disease in History

    FALLOPIUS -- 1561 de la PEYRONIE -- 1743 INDURATIO PLASTICA PENE FALLOPIUS -- 1561 de la PEYRONIE -- 1743 Peyronie’s Disease in History

  112. Slide 112: Peyronie's Disease In History

    Peyronie’s Disease In History

  113. Slide 113: Peyronie's Disease

    Incurable Reassurance Medical Therapy Surgery Incurable Reassurance Medical Therapy Surgery * Peyronie’s Disease

  114. Slide 114: Peyronie's Disease

    Fibrous Lesions - Impede Expansion Curvature And / Or Indentation And / Or Foreshortening Fibrous Lesions - Impede Expansion Curvature And / Or Indentation And / Or Foreshortening Peyronie’s Disease

  115. Slide 115: Peyronie's Disease Update

    Peyronie’s Disease Update

  116. Slide 116: Incidence of Peyronie's Disease

    Beta Blockers Phenytoin Paget’s Disease Diabetes Mellitus Beta Blockers Phenytoin Paget’s Disease Diabetes Mellitus Incidence of Peyronie’s Disease

  117. Slide 117: Incidence of Peyronie's Disease

    Familial Dupuytren’s 15 - 30 % 10 - 40 % Autosomal Dominant Nyberg. JU, 1982; Ralph. JU, 1997 Familial Dupuytren’s 15 - 30 % 10 - 40 % Autosomal Dominant Nyberg. JU, 1982; Ralph. JU, 1997 Incidence of Peyronie’s Disease

  118. Slide 118: Incidence of Peyronie's Disease

    1 - 100 Age of Onset - 53yrs (MEAN) Prevalence - 0.4 % Rheu Arth, Hypertension Asymptomatic Prevalence: 22 / 100 Jordan. Cont Urol, 1999, Lindsay. JU, 1991; Smith. Am J Clin Path, 1969 Incidence of Peyronie’s Disease

  119. Slide 119: Incidence of Peyronie's Disease

    45 - 65 Years PEAK MID 50’s Loss Of Tissue Elasticity Erectile Dysfunction *** 45 - 65 Years PEAK MID 50’s Loss Of Tissue Elasticity Erectile Dysfunction Incidence of Peyronie’s Disease

  120. Slide 120: Causes of Peyronie's Disease

    Trauma - Insertion Septum Localized Aberration Wound Healing Associated With ED Associated Fibrin Deposition Devine. JU, 1997, Jarow. JU, 1997, Somers. JU, 1997 Causes of Peyronie’s Disease Trauma - Insertion Septum Localized Aberration Wound Healing Associated With ED Associated Fibrin Deposition D

  121. Slide 121: Etiology – Trauma

    Midline Septal Insertion - Vulnerable with Buckling Devine. JU, 1997, Jarow. JU, 1997, Gelbard, 1993 Etiology - Trauma Midline Septal Insertion - Vulnerable with Buckling Devine. JU, 1997, Jarow. JU, 1997, Gelbard, 1993

  122. Slide 122: Etiology – Genetics

    Paget’s Disease Of The Bone Dupuytren's Contracture Certain HLA Subtypes Autoimmune Disease Hyperactive Wound Healing Lyles. J Bone/Mineral Res, 1997, Nyberg. JU, 1982, Nyberg. JU, 1997, Ralph. JU, 1997, Leffell. JU, 1997 Schiavino. Uro, 1997, Stewart. JU, 1994, Devine. Clin Plas Surg, 1988, Diegelm

  123. Slide 123: Pathology

    Round Cell Infiltration Obliterated Space of Smith Fibrin Deposits Smith. Am J Clin Path,1969, Devine. JU,1997, Somers. JU,1997 Pathology Round Cell Infiltration Obliterated Space of Smith Fibrin Deposits Smith. Am J Clin Path,1969, Devine. JU,1997, Somers. JU,1997

  124. Slide 124: Pathology – Round Cell Infiltration

    Smith. Am J Clin Path,1969, Devine. JU,1997 Pathology – Round Cell Infiltration; Obliterated Space of Smith Smith. Am J Clin Path,1969, Devine. JU,1997

  125. Slide 125: Pathology – Fibrin Deposits

    Somers. JU,1997 Pathology – Fibrin Deposits Somers. JU,1997

  126. Slide 126: Pathology

    Dense Collagen Decreased Elastin Dystrophic Calcification Cartilaginous Metaplasia Gelbard. JU,1988, Ehrlich. JU,1997 Pathology Dense Collagen Decreased Elastin Dystrophic Calcification Cartilaginous Metaplasia Gelbard. JU,1988, Ehrlich. JU,1997

  127. Slide 127: Anatomy – Tunica Albuginea

    Multilayered 1.5 - 3.0 mm thick Incompetent Septum Longitudinal Layer Thinnest 3 - 9 O’clock Hsu et al. Int J Imp,1992, Brock et al. JU,1997 Anatomy - Tunica Albuginea Multilayered 1.5 - 3.0 mm thick Incompetent Septum Longitudinal Layer Thinnest - O’clock Hsu et al. Int J Imp,1992, Brock et al. JU,

  128. Slide 128: Anatomy – Tunica Albuginea

    Dorsal Opposite Ventral - Upward Bending Septum Joins Circ Layer - Delamination Ralph. JU,1997, Devine. Clin Plast Surg,1988, Jarow. JU,1997, Devine. JU,1997 Anatomy - Tunica Albuginea

  129. Slide 129: Anatomy – Tunica Albuginea

    Plaque Usually Dorsal Devine. JU, 1997, Gelbard. JU, 1993, El-Saka et al. Bju,1997 Anatomy - Tunica Albuginea

  130. Slide 130: Anatomy – Tunica Albuginea

    Compliance of the Tunica Collagen is Brittle Elastin Stretches Helical Arrangement Straightens Elastin Stretches Ground Substance Displaces Anatomy - Tunica Albuginea Compliance of the Tunica Collagen is Brittle Elastin Stretches Helical Arrangement Straightens Elastin Stretches Ground Substance Dis

  131. Slide 131: Peyronie's Disease Update

    Peyronie’s Disease Update

  132. Slide 132: Molecular Basis of Injury

    Repeated Mechanical Stress - Microvascular Trauma Delamination Bleeding Fibrinogen Devine. JU,1997, Jarow. JU,1997, Devine. Clin Plas Surg,1988 Molecular Basis of Injury Molecular Basis of Injury

  133. Slide 133: Molecular Basis of Injury

    Pain And Inflammation Vasoactive Factors Is The Inflammatory Response “Trapped?” PDGF-A and PDGF-B, TGF-b1 Diegelman. JU,1997, Van de Water. JU,1997, Somers. JU,1997 Molecular Basis of Injury Molecular Basis of Injury

  134. Slide 134: Molecular Basis of Injury

    Causes Increased Connective Tissue Inhibits Collagenases Can Induce It’s Own Production Border. NEJM,1994, Border. J Clin Inves,1992, Moreland. Int J Impot,1998 Implicated in Soft Tissue Fibrosis Implicated in ED Increases Synthesis of Fibroblasts – Fibrosis Wound Healing TGF-b1 Molecular Basis of I

  135. Slide 135: Disease Progression

    Active Phase Painful Erections – Sometimes Changing Deformity Secondary Phase Pain Resolves Stable Deformity Gelbard. JU, 1990, Williams. JU, 1970 Active Phase Painful Erections – Sometimes Changing Deformity Secondary Phase Pain Resolves Stable Deformity Gelbard. JU, 1990, Williams. JU, 1970 * Dise

  136. Slide 136: Psychological Aspects

    Poorly Defined in the Literature Mentioned Only In Passing Lowsley. JU, 1950, Gelbard. JU,1990, Williams. JU, 1970, Devine. JU, 1974, Mellman, Ju 1978, Pryor. JU, 1979, Ralph. Bju ,1992, Jones. JU, 1984 Poorly Defined in the Literature Mentioned Only In Passing Lowsley. JU, 1950, Gelbard. JU,1990, W

  137. Slide 137: Psychological Aspects

    Disturbed Body Image Fearful Of Treatment Many Functional Aspects of ED Like “Death” Denial Ambivalence Anxiety Depression Shame Embarrassment Self Disgust Jones. AUA Update, 1998, Rosen. Data In Process, 2005 Disturbed Body Image Fearful Of Treatment Many Functional Aspects of ED Like “Death” Denia

  138. Slide 138: Psychological Aspects

    Youthful Libido Aging Tissues Relate With Intercourse Do Not “ Like ” To Talk About the Problem Jones. AUA Update, 1998, Rosen. Data In Process, 2005 Youthful Libido Aging Tissues Relate With Intercourse Do Not “ Like ” To Talk About the Problem Jones. AUA Update, 1998, Rosen. Data In Process, 2005

  139. Slide 139: Psychological Aspects

    Most Patients: Told “End Of Sex Life” Admit … Are Coping Poorly Believe “Sex Is Intercourse” Must Be Told To Keep “Sexual Expression Alive” Jones. AUA Update, 1998 Most Patients: Told “End Of Sex Life” Admit … Are Coping Poorly Believe “Sex Is Intercourse” Must Be Told To Keep “Sexual Expression Ali

  140. Slide 140: Clinical Features

    Plaque or Induration: Usually Located Dorsal Septal Insertion Can Be Multiple Can Involve Septal Fibers Patients May Not Be Aware Burford. JU, 1943, Bystrom.Scan J Urol Neph,1976, Williams. BJU, 1980, Furlow. JU, 1975 Plaque or Induration: Usually Located Dorsal Septal Insertion Can Be Multiple Can

  141. Slide 141: Clinical Features

    Penile Pain: Usually Only With Erection Usually Not Severe But Can Interfere With Intercourse Spontaneous Improvement The Rule As Inflammation Resolves Burford. JU, 1943, Gelbard. JU, 1990, Williams. BJU, 1980, Furlow. JU, 1975 Clinical Features

  142. Slide 142: Clinical Features

    Curvature and/or Deformity: Usually Dorsal Curve Curvature Can Be Complex Lateral or Ventral – Disabling Can Cause Indentation Burford. JU, 1943, Gelbard. JU, 1990, Williams. BJU, 1980, Furlow. JU, 1975 Clinical Features

  143. Slide 143: Clinical Features

    Clinical Features

  144. Slide 144: Clinical Features

    Erectile Dysfunction: Reported Incidence - Variable Bystrom. Scan J Urol Neph,1976, Levine. JU,1996, Stecker. JU,1984, Jordan. JU,1993, Furlow. JU,1975, Gasior. WJU,1990, Amin. Bj Rad,1993, Montorsi. JU,1994, Pryor. ACTA UROL BELG,1998, Lopez et al. JU,1993, Chilton. BJU,1982, Ralph. BJU,1992, Metz.

  145. Slide 145: Clinical Features

    Reduced Elastin - Increased Type III Collagen Associated with Veno-occlusive Problems Cavernosal Fibrosis Can Interfere with Arterial Flow Chisang et al. Euro Urol,1992, Akkus et al. BJU,1997, Ralph. BJU,1992 Clinical Features

  146. Slide 146: Medical Management – Oral

    Vitamin E (tocopherol) – antioxidant Potaba (Para Aminobenzoate) Allegra (Seldane) Colchicine Tamoxifen Carnitine (Acetyl-L-Carnitine/Propionyl- L-Carnitine) Trental (Pentoxifylline) Natulan (Procarbazine) Steroids or NSAIDs PDE-5 Inhibitors Vitamin E (tocopherol) – antioxidant Potaba (Para Aminoben

  147. Slide 147: Medical Management – Oral

    Rigorous Well Designed / Controlled Studies Are Needed As It Stands Now, The Role Of Oral Therapy To Alter The Progress Of Peyronie's Disease Is Probably Limited To The Acute Phase Of Disease Mynderse And Monga, I J Imp Res, 2002 Medical Management - Oral

  148. Slide 148: Medical Management – Intralesional Injection

    Steroids Parathyroid Hormone Orgotein Verapamil Interferon -2b Steroids Parathyroid Hormone Orgotein Verapamil Interferon -2b Medical Management – Intralesional Injection

  149. Slide 149: Medical Management – Topicals

    Steroids, Verapamil, Beta – Aminopropionitrile, Orgotein Transcutaneous Absorption of Drug No Blinded / Controlled Studies No Proven Efficacy - Single Reports Only Medical Management - Topicals Steroids, Verapamil, Beta – Aminopropionitrile, Orgotein Transcutaneous Absorption of Drug No Blinded / Co

  150. Slide 150: Medical Management – Iontophoresis / Electromotive Therapy

    Steroids, Verapamil, Orgotein, Histamine Enhanced Transcutaneous Absorption Of Drug Using Surface Delivered Heat Or Current No Blinded / Controlled Studies No Proven Efficacy - Single Reports Only Medical Management – Iontophoresis / Electromotive Therapy Steroids, Verapamil, Orgotein, Histamine Enh

  151. Slide 151: Non-Surgical Management

    Lithotripsy Questionable Rationale - Ostensibly Mechanical Disruption of the Plaque Enhancing Compliance No Blinded / Controlled Studies No Proven Efficacy To Date, ? Ill Effects on the Erectile Tissue, ? Adjuvant to Intralesional Injection Bellorofonte. Arch Ital Urol Neph Androl,1988 Hauck JU, 200

  152. Slide 152: Medical Management – Combined Therapy

    Intralesional Injection And Oral Interferon ~ -2b + Vit E Verapamil + Carnitine Verapamil + Tamoxifen Oral Vit E + Colchicine Lithotripsy + Intralesional Verapamil Birmngham Study Underway Ved + Intralesional Verapamil Study Protocol Under Evaluation Hellstrom, Bju Int 2003, Prieto Castro, Bju Int 2

  153. Slide 153: Medical Management – Future Directions

    Investigations Suggest That Part Of The Peyronie’s Process Involves Supression Of “Antifibrotics” Matrixmetalloproteinases 1 Antitrypsin Cyclic GMP Lue . J Sex Med 2005, Hauck. J Sex Med 2005 ~ Medical Management - Future Directions

  154. Slide 154: Surgical Management Indications

    When The Deformity Precludes Intercourse Erectile Dysfunction Precludes Intercourse Surgical Management Indications

  155. Slide 155: Surgical Management Pre-operative Assessment

    Stable / Quiescent Disease Usually > 1yr from onset of symptoms Stable deformity for 3 – 5 Mos Pain Free Detailed Assessment of Erectile Function CDU DICC True Informed Consent Surgical Management Pre-operative Assessment Stable / Quiescent Disease Usually > 1yr from onset of symptoms Stable deformi

  156. Slide 156: Surgical Management Options

    Plication Or Tunical Resection Tunical Resection With Plicating Closure Corporoplasty Nesbitt. Ju 1965, Ebbehoj. Urol 1985, Essed. Urol 1985, Lue. Ju 1998, Geertsen. Bju 1996, Emberger. Bju 1984, Sassine. Urol 1994, Kelami. Bju 1987, Licht. Ju 1997, Yachia. Ju 1990, Rehman. Ju 1997;Pryor And Fitzpat

  157. Slide 157: Surgical Management Options: Plication Or Tunical Resection

    Plication Or Tunical Resection Surgical Management Options

  158. Slide 158: Surgical Management Options: Excision / Incision With Grafting

    Excision / Incision With Grafting Surgical Management Options Excision / Incision With Grafting

  159. Slide 159: Surgical Management Options

    Surgical Management Options

  160. Slide 160: Surgical Management Options: Prosthetic Implantation

    Prosthetic Implantation With Straightening Pryor. Churchill-Livingston, 1987, Wilson. JU, 1994, Montague. JU, 1006, Knoll. Urol, 1990, Eigner. JU, 1991, Carson. Ijir, 1998, Carwson. Ijir, 2002 Surgical Management Options

  161. Slide 161: Medical Management – XIAFLEX

    Clostridial Collagenase (XIAFLEX) Creation of “Chemical Incisions” with Initiation of Remodeling Blinded / Controlled Studies Underway Available Only on Protocol Gelbard. Urol Res, 1982, Gelbard. JU,1985, Gelbard. JU,1993, National Collagenase Study Group, Jordan. J Sexual Medicine, 2007 Medical Man

  162. Slide 162: Safety and Efficacy of XIAFLEX in Peyronie's Disease

    Safety and Efficacy of Injectable Mixed Collagenase Subtypes (XIAFLEX) in the Treatment of Peyronie’s Disease Safety and Efficacy of Injectable Mixed Collagenase Subtypes (XIAFLEX) in the Treatment of Peyronie’s Disease

  163. Slide 163: Objectives

    To assess the impact of injectable mixed collagenase subtypes (XIAFLEX, Auxilium) on the angle of penile deviation and plaque size To assess the tolerability and safety of XAIFLEX for the treatment of Peyronie’s disease Objectives

  164. Slide 164: Methods: Study Design

    Baseline Week 12 Month 6 Follow-up Month 9 Follow-up 3 injections (7 10 d) 3 injections (7 10 d) X X X X X X Baseline Week 12 Month 6 Follow-up Month 9 Follow-up 3 injections (5 10 d) 3 injections (5 10 d) Week 6 3 injections (5 10 d) X X X X X X X X X Methods: Study Design Study A (N=25) Study B (N

  165. Slide 165: Methods: Patients

    Key inclusion criteria: Men aged 18 75 years Diagnosis of Peyronie’s disease Key exclusion criteria: Prior surgery for Peyronie’s disease Extensively calcified plaque Substantial erectile deficits due to Peyronie’s disease Penile bend <20 degrees Sexual dysfunction due to other causes Methods: Patie

  166. Slide 166: Assessment of Efficacy and Tolerability

    Study A: Primary: changes from baseline in the angle of deviation and plaque size Secondary: patient responses on VAS for pain and sexual function Secondary: investigators’ global evaluation of change Study B: Primary: patients’ responses on the Peyronie’s Patient Questionnaire at month 9 Secondary:

  167. Slide 167: Results: Demographics and Disposition

    Study A: 25 men enrolled and 18 completed the study Mean age was 55 years; 92% were white Mean duration of illness was 39 months Study B: 10 men enrolled; 9 completed the study Mean age was 58 years; 90% were white Mean duration of illness was 32 months Results: Demographics and Disposition Study A:

  168. Slide 168: Results: Clinical Success, Deviation Angle

    58 53 35 0 20 40 60 80 100 M3 M6 M9 50 100 100 89 0 20 40 60 80 100 W6 M3 M6 M9 *Clinical success: 25% reduction in the angle of deviation. Results: Clinical Success,* Deviation Angle Study A Study B

  169. Slide 169: Results: Clinical Success, Plaque Size

    95 65 67 0 20 40 60 80 100 M3 M6 M9 *Clinical success: 25% reduction in plaque size. Results: Clinical Success,* Plaque Size Study A

  170. Slide 170: Results: Mean Change From Baseline in Deviation Angle and Plaque Size

    Deviation Angle ( ) Plaque Length (cm) Plaque Width (cm) Study A Study B Study A Study B Study A Study B Baseline 52.8 50.2 5.8 7.85 0.80 0.48 W6 NA 15.2* NA 0.05 NA 0.16 M3 12.7* 20.6 † 0.94 † 1.59 0.13* 0.11 M6 11.1 † 28.4 † 0.48 ‡ 0.11 0.15 ‡ 0.21 ‡ M9 6.6 26.2 † 0.68 0.00 0.12 ‡ 0.18 * P 0.007 v

  171. Slide 171: Results: Peyronie's Patient Questionnaire (Study B)

    Patient-reported improvements in sexual function were observed for: Enjoyment of intercourse ( P =0.023) Satisfaction with sexual relationships ( P =0.043) Freedom from pain during erection ( P =0.009) At baseline, 4 patients reported no sexual activity, and at month 9, 100% (9/9) were sexually acti

  172. Slide 172: Results: Physical Symptoms (Study B)

    Pain with erection: resolved in 6 patients Plaque palpability: disappeared in 4 patients with moderate-to-severe palpation Penile indentation: disappeared in 3 patients and improved from severe to moderate in 1 patient Penile shortening: improved from severe to moderate in 1 patient Penile numbness:

  173. Slide 173: Results: Investigators' Global Assessment of Patients

    59 53 56 0 20 40 60 80 100 M3 M6 M9 50 67 67 67 0 20 40 60 80 100 W6 M3 M6 M9 Results: Investigators’ Global Assessment of Patients Much Improved/Very Much Improved Study A Study B

  174. Slide 174: Adverse Events: Study A

    Relationship to Study Drug, n (%) Adverse Event Possibly Probably Definitely Reproductive system 1 (4) 1 (4) 14 (56) Erectile disturbance 0 (0) 1 (4) 0 (0) Penile disorder NOS 0 (0) 0 (0) 5 (20) Penile pain 1 (4) 0 (0) 12 (48) Penile swelling 0 (0) 0 (0) 6 (24) Skin and subcutaneous tissue disorders

  175. Slide 175: Adverse Events: Study B

    Treatment-Related Adverse Event, n (%) Total (N=10) General disorders and administration site conditions 5 (50) Local swelling 2 (20) Suprapubic pain 4 (40) Injury, poisoning, and procedural pain 10 (100) Contusion 10 (100) Reproductive system and breast disorders 9 (90) Erectile dysfunction 1 (10)

  176. Slide 176: Adverse Events

    The most common treatment-related adverse events were localized administration site reactions of mild intensity and of limited duration (typically within 3 weeks) The most common adverse events were contusion, penile pain, and ecchymosis All adverse events resolved without medical intervention Adver

  177. Slide 177: Conclusions

    XIAFLEX, administered in up to 3 series of multiple injections, appears to be effective for the treatment of Peyronie’s disease Treatment with XIAFLEX was generally well tolerated Larger controlled clinical trials are needed to confirm these promising results and are in the process of development Co

  178. Slide 178: Peyronie's Disease

    Gerald H. Jordan, MD Department of Urology Eastern Virginia Medical School Norfolk, VA Peyronie’s Disease Gerald H. Jordan, MD Department of Urology Eastern Virginia Medical School Norfolk, VA

  179. Slide 179: Development Plans for Peyronie's Disease

    Development Plans for Peyronie ’ s Disease Jyrki Mattila Executive Vice President R&D

  180. Slide 180: Preclinical local tolerability study

    Preclinical local tolerability study • Four anatomic structures exposed to Xiaflex ™ ~ Tunica albuginea, Corpus cavernosum, NAV-complex and Urethra • Single dose and repeated dose groups • Dosing mimics expected clinical use • Histopathology, toxicokinetics and immunogenecity to be recorded • Study

  181. Slide 181: Phase 2b study

    Phase 2 b study • Injections of 0.58 mg in 0.25 mL volume given into Peyronie’s plaque ~ Two regimens of either six or nine total doses to be compared Patient Reported Outcome Survey likely to be used as a primary endpoint ~ AUXL developed its own proprietary questionnaire for Peyronie’s disease ~ F

  182. Slide 182: Market Overview for XIAFLEX: Peyronie's Disease

    Market Overview for XIAFLEX: Peyronie ’ s Disease Roger D. Graham, Jr. Executive Vice President Sales & Marketing

  183. Slide 183: Market Research Methodology

    Market Research Methodology • Approximately 600 Urologists/Surgeons ~ 415 U.S. Physicians ~ 193 E.U. Physicians Qualitative and Quantitative Research ~ on in depth interviews with KOLs (High Treaters) ~ Web based Surveys ~ Second quantitative study designed to provide 95% confidence level and 7.5% m

  184. Slide 184: Surgeon Motivation to Use Xiaflex

    Surgeon Motivation to Use Xiaflex • Seeking effective treatment options ~ No effective medical therapy ~ Surgery is last resort; many patients choose not to have it ~ Penile shortening ~ Erectile dysfunction/impotence ~ Many surgical patients dissatisfied with outcomes High Interest In XIAFLEX ~ Hig

  185. Slide 185: Reimbursement and Surgical Costs

    Reimbursement and Surgical Costs • All payers (US & EU) anticipate coverage for XIAFLEX • New CPT codes may be needed • Ambulatory (70%) & In-Patient (30%) Surgery ~ Approximate Cost (Blended) $ 13,000* • In-patient Surgery ~ $ 23,000** * Pharmetrics ** Verispan Approximate Cost

  186. Slide 186: XIAFLEX Potential: Peyronie's Disease

    XIAFLEX Potential: Peyronie’s Disease Patients Seeking Treatment ~475,000 Surgery Not Recommended ~365,000 Watchful Waiting ~160,000 Medical or Intralesional Therapy ~205,000 Surgery Recommended ~110,000 XIAFLEX Potential Candidates ~210,000 ~ 135,000 in U.S. ~ 75,000 in Europe Source: Auxilium rese

  187. Slide 187: Xiaflex Commercial Opportunity

    Xiaflex Commercial Opportunity We believe: • High need opportunity (MD and Patient) • Surgeons and patients prefer non-invasive treatment • Early indication that each patient will require 6 to 9 vials of Xiaflex • Reimbursement environment is positive • Peyronie’s represents a second significant com

  188. Slide 188: XIAFLEX (clostridial collagenase for injection)

    AIAFLEX lostridal colagenase for injection

Auxilium Pharmaceuticals — Investor Day (October 2007) on 6ix